DK1664795T3 - Diagnostisk fremgangsmåde for hjerneskaderelaterede lidelser - Google Patents
Diagnostisk fremgangsmåde for hjerneskaderelaterede lidelser Download PDFInfo
- Publication number
- DK1664795T3 DK1664795T3 DK04787496.1T DK04787496T DK1664795T3 DK 1664795 T3 DK1664795 T3 DK 1664795T3 DK 04787496 T DK04787496 T DK 04787496T DK 1664795 T3 DK1664795 T3 DK 1664795T3
- Authority
- DK
- Denmark
- Prior art keywords
- fabp
- stroke
- protein
- antibody
- polypeptide
- Prior art date
Links
- 208000029028 brain injury Diseases 0.000 title claims description 69
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 65
- 238000002405 diagnostic procedure Methods 0.000 title claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 104
- 229920001184 polypeptide Polymers 0.000 claims description 103
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 100
- 208000006011 Stroke Diseases 0.000 claims description 96
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 84
- 102000011026 Fatty Acid Binding Protein 3 Human genes 0.000 claims description 75
- 108010062715 Fatty Acid Binding Protein 3 Proteins 0.000 claims description 75
- 101710163063 Ubiquitin fusion degradation protein 1 homolog Proteins 0.000 claims description 58
- 101710094461 Ubiquitin recognition factor in ER-associated degradation protein 1 Proteins 0.000 claims description 58
- 238000003556 assay Methods 0.000 claims description 55
- 102100023252 Nucleoside diphosphate kinase A Human genes 0.000 claims description 50
- 238000000034 method Methods 0.000 claims description 49
- 108010072220 Cyclophilin A Proteins 0.000 claims description 42
- 102100034539 Peptidyl-prolyl cis-trans isomerase A Human genes 0.000 claims description 42
- 108090000623 proteins and genes Proteins 0.000 claims description 40
- 102000004169 proteins and genes Human genes 0.000 claims description 40
- 102100038833 Ubiquitin recognition factor in ER-associated degradation protein 1 Human genes 0.000 claims description 35
- 238000003745 diagnosis Methods 0.000 claims description 35
- 230000001105 regulatory effect Effects 0.000 claims description 35
- 230000004570 RNA-binding Effects 0.000 claims description 31
- 210000001124 body fluid Anatomy 0.000 claims description 31
- 239000010839 body fluid Substances 0.000 claims description 31
- 210000002381 plasma Anatomy 0.000 claims description 31
- 108010081372 NM23 Nucleoside Diphosphate Kinases Proteins 0.000 claims description 27
- 102000007456 Peroxiredoxin Human genes 0.000 claims description 26
- 108030002458 peroxiredoxin Proteins 0.000 claims description 26
- 238000002965 ELISA Methods 0.000 claims description 24
- 102000007659 Protein Deglycase DJ-1 Human genes 0.000 claims description 24
- 108010032428 Protein Deglycase DJ-1 Proteins 0.000 claims description 24
- 238000001514 detection method Methods 0.000 claims description 24
- 102000048176 Prostaglandin-D synthases Human genes 0.000 claims description 23
- 108030003866 Prostaglandin-D synthases Proteins 0.000 claims description 23
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 claims description 19
- 208000032109 Transient ischaemic attack Diseases 0.000 claims description 19
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 claims description 19
- 102100035632 Calcyphosin Human genes 0.000 claims description 17
- 101710085913 Calcyphosin Proteins 0.000 claims description 17
- 102000003908 Cathepsin D Human genes 0.000 claims description 17
- 108090000258 Cathepsin D Proteins 0.000 claims description 17
- 102100039289 Glial fibrillary acidic protein Human genes 0.000 claims description 17
- 102000008763 Neurofilament Proteins Human genes 0.000 claims description 17
- 108010088373 Neurofilament Proteins Proteins 0.000 claims description 17
- 102100023206 Neuromodulin Human genes 0.000 claims description 17
- 101710144282 Neuromodulin Proteins 0.000 claims description 17
- 102100025038 Ubiquitin carboxyl-terminal hydrolase isozyme L1 Human genes 0.000 claims description 17
- 101710186825 Ubiquitin carboxyl-terminal hydrolase isozyme L1 Proteins 0.000 claims description 17
- 210000005044 neurofilament Anatomy 0.000 claims description 17
- 201000010875 transient cerebral ischemia Diseases 0.000 claims description 17
- 230000001900 immune effect Effects 0.000 claims description 14
- 210000002966 serum Anatomy 0.000 claims description 12
- 208000016988 Hemorrhagic Stroke Diseases 0.000 claims description 11
- 238000004422 calculation algorithm Methods 0.000 claims description 10
- 208000032382 Ischaemic stroke Diseases 0.000 claims description 9
- 239000000758 substrate Substances 0.000 claims description 9
- 206010019196 Head injury Diseases 0.000 claims description 8
- 201000004810 Vascular dementia Diseases 0.000 claims description 8
- 206010018985 Haemorrhage intracranial Diseases 0.000 claims description 7
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 claims description 7
- 210000004369 blood Anatomy 0.000 claims description 7
- 239000008280 blood Substances 0.000 claims description 7
- 208000020658 intracerebral hemorrhage Diseases 0.000 claims description 7
- 239000007787 solid Substances 0.000 claims description 6
- -1 D synthase Proteins 0.000 claims description 4
- 238000004393 prognosis Methods 0.000 claims description 4
- 230000027455 binding Effects 0.000 claims description 3
- 230000006378 damage Effects 0.000 claims description 3
- 102000005720 Glutathione transferase Human genes 0.000 claims 3
- 108010070675 Glutathione transferase Proteins 0.000 claims 3
- 101710179452 Ubiquitin fusion degradation protein 1 Proteins 0.000 claims 3
- 208000027418 Wounds and injury Diseases 0.000 claims 2
- 208000014674 injury Diseases 0.000 claims 2
- 230000006931 brain damage Effects 0.000 description 60
- 231100000874 brain damage Toxicity 0.000 description 59
- 208000035475 disorder Diseases 0.000 description 52
- 235000018102 proteins Nutrition 0.000 description 38
- 239000000499 gel Substances 0.000 description 37
- 239000000523 sample Substances 0.000 description 37
- 238000000539 two dimensional gel electrophoresis Methods 0.000 description 31
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 28
- 239000000463 material Substances 0.000 description 27
- 239000000090 biomarker Substances 0.000 description 25
- 101710149890 Nucleoside diphosphate kinase A Proteins 0.000 description 23
- 238000012549 training Methods 0.000 description 23
- 206010000891 acute myocardial infarction Diseases 0.000 description 18
- 239000003550 marker Substances 0.000 description 18
- 101000573172 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) Nucleoside diphosphate kinase Proteins 0.000 description 17
- 108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 15
- 102000012288 Phosphopyruvate Hydratase Human genes 0.000 description 15
- 108010024636 Glutathione Proteins 0.000 description 14
- 229960003180 glutathione Drugs 0.000 description 14
- 102000013394 Troponin I Human genes 0.000 description 13
- 108010065729 Troponin I Proteins 0.000 description 13
- 230000004481 post-translational protein modification Effects 0.000 description 13
- 230000035945 sensitivity Effects 0.000 description 13
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 12
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 12
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 12
- 102100037733 Fatty acid-binding protein, brain Human genes 0.000 description 12
- 101710098548 Fatty acid-binding protein, brain Proteins 0.000 description 12
- 238000005259 measurement Methods 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 102100030421 Fatty acid-binding protein 5 Human genes 0.000 description 10
- 101710083187 Fatty acid-binding protein 5 Proteins 0.000 description 10
- 102100030431 Fatty acid-binding protein, adipocyte Human genes 0.000 description 10
- 101710118908 Fatty acid-binding protein, adipocyte Proteins 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 10
- 210000004556 brain Anatomy 0.000 description 10
- 238000005406 washing Methods 0.000 description 10
- 101100226596 Gallus gallus FABP gene Proteins 0.000 description 9
- 102100021487 Protein S100-B Human genes 0.000 description 9
- 239000000427 antigen Substances 0.000 description 9
- 102000036639 antigens Human genes 0.000 description 9
- 108091007433 antigens Proteins 0.000 description 9
- 239000013024 dilution buffer Substances 0.000 description 9
- 238000003018 immunoassay Methods 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 230000000302 ischemic effect Effects 0.000 description 7
- 230000002378 acidificating effect Effects 0.000 description 6
- 238000001962 electrophoresis Methods 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 230000036470 plasma concentration Effects 0.000 description 6
- 239000007790 solid phase Substances 0.000 description 6
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 5
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 5
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 230000000926 neurological effect Effects 0.000 description 5
- 229910052709 silver Inorganic materials 0.000 description 5
- 239000004332 silver Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- DVLFYONBTKHTER-UHFFFAOYSA-N 3-(N-morpholino)propanesulfonic acid Chemical compound OS(=O)(=O)CCCN1CCOCC1 DVLFYONBTKHTER-UHFFFAOYSA-N 0.000 description 4
- 208000008574 Intracranial Hemorrhages Diseases 0.000 description 4
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000002008 hemorrhagic effect Effects 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 239000011859 microparticle Substances 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 238000007619 statistical method Methods 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 101710159080 Aconitate hydratase A Proteins 0.000 description 3
- 101710159078 Aconitate hydratase B Proteins 0.000 description 3
- 206010008190 Cerebrovascular accident Diseases 0.000 description 3
- 102000053171 Glial Fibrillary Acidic Human genes 0.000 description 3
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 3
- 102000019298 Lipocalin Human genes 0.000 description 3
- 108050006654 Lipocalin Proteins 0.000 description 3
- 230000004988 N-glycosylation Effects 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 3
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 3
- 208000024777 Prion disease Diseases 0.000 description 3
- 102000044126 RNA-Binding Proteins Human genes 0.000 description 3
- 101710105008 RNA-binding protein Proteins 0.000 description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 238000000540 analysis of variance Methods 0.000 description 3
- 239000012491 analyte Substances 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 210000000133 brain stem Anatomy 0.000 description 3
- 238000011088 calibration curve Methods 0.000 description 3
- 208000026106 cerebrovascular disease Diseases 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 208000028867 ischemia Diseases 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 208000015122 neurodegenerative disease Diseases 0.000 description 3
- 230000007971 neurological deficit Effects 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 2
- NGSWKAQJJWESNS-UHFFFAOYSA-N 4-coumaric acid Chemical compound OC(=O)C=CC1=CC=C(O)C=C1 NGSWKAQJJWESNS-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 208000002109 Argyria Diseases 0.000 description 2
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- 208000011990 Corticobasal Degeneration Diseases 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- 102000030914 Fatty Acid-Binding Human genes 0.000 description 2
- 201000011240 Frontotemporal dementia Diseases 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 2
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 2
- 208000004552 Lacunar Stroke Diseases 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 238000000585 Mann–Whitney U test Methods 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 208000025966 Neurological disease Diseases 0.000 description 2
- 239000002033 PVDF binder Substances 0.000 description 2
- 206010034010 Parkinsonism Diseases 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- 101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 description 2
- 101710122255 Protein S100-B Proteins 0.000 description 2
- 102000013674 S-100 Human genes 0.000 description 2
- 108700021018 S100 Proteins 0.000 description 2
- 101100226329 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) EXO84 gene Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000018756 Variant Creutzfeldt-Jakob disease Diseases 0.000 description 2
- BTKMJKKKZATLBU-UHFFFAOYSA-N [2-(1,3-benzothiazol-2-yl)-1,3-benzothiazol-6-yl] dihydrogen phosphate Chemical compound C1=CC=C2SC(C3=NC4=CC=C(C=C4S3)OP(O)(=O)O)=NC2=C1 BTKMJKKKZATLBU-UHFFFAOYSA-N 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 238000012742 biochemical analysis Methods 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 208000005881 bovine spongiform encephalopathy Diseases 0.000 description 2
- 230000003683 cardiac damage Effects 0.000 description 2
- 230000008809 cell oxidative stress Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000013065 commercial product Substances 0.000 description 2
- 238000010835 comparative analysis Methods 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 229960003624 creatine Drugs 0.000 description 2
- 239000006046 creatine Substances 0.000 description 2
- 239000001177 diphosphate Substances 0.000 description 2
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 2
- 235000011180 diphosphates Nutrition 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000002565 electrocardiography Methods 0.000 description 2
- 108091022862 fatty acid binding Proteins 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000002518 glial effect Effects 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 238000009593 lumbar puncture Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 230000000626 neurodegenerative effect Effects 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000003118 sandwich ELISA Methods 0.000 description 2
- 230000000405 serological effect Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 102000013498 tau Proteins Human genes 0.000 description 2
- 108010026424 tau Proteins Proteins 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000010626 work up procedure Methods 0.000 description 2
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 1
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 1
- HKJKONMZMPUGHJ-UHFFFAOYSA-N 4-amino-5-hydroxy-3-[(4-nitrophenyl)diazenyl]-6-phenyldiazenylnaphthalene-2,7-disulfonic acid Chemical compound OS(=O)(=O)C1=CC2=CC(S(O)(=O)=O)=C(N=NC=3C=CC=CC=3)C(O)=C2C(N)=C1N=NC1=CC=C([N+]([O-])=O)C=C1 HKJKONMZMPUGHJ-UHFFFAOYSA-N 0.000 description 1
- VSMDINRNYYEDRN-UHFFFAOYSA-N 4-iodophenol Chemical compound OC1=CC=C(I)C=C1 VSMDINRNYYEDRN-UHFFFAOYSA-N 0.000 description 1
- ITZMJCSORYKOSI-AJNGGQMLSA-N APGPR Enterostatin Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N1[C@H](C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)CCC1 ITZMJCSORYKOSI-AJNGGQMLSA-N 0.000 description 1
- 240000004731 Acer pseudoplatanus Species 0.000 description 1
- 206010052075 Acquired epileptic aphasia Diseases 0.000 description 1
- 102000007592 Apolipoproteins Human genes 0.000 description 1
- 108010071619 Apolipoproteins Proteins 0.000 description 1
- 238000006677 Appel reaction Methods 0.000 description 1
- BHELIUBJHYAEDK-OAIUPTLZSA-N Aspoxicillin Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3[C@H](C(C)(C)S[C@@H]32)C(O)=O)=O)NC(=O)[C@H](N)CC(=O)NC)=CC=C(O)C=C1 BHELIUBJHYAEDK-OAIUPTLZSA-N 0.000 description 1
- 102000007371 Ataxin-3 Human genes 0.000 description 1
- 208000006373 Bell palsy Diseases 0.000 description 1
- 208000034577 Benign intracranial hypertension Diseases 0.000 description 1
- 208000024806 Brain atrophy Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000004420 Creatine Kinase Human genes 0.000 description 1
- 108010042126 Creatine kinase Proteins 0.000 description 1
- 201000003863 Dandy-Walker Syndrome Diseases 0.000 description 1
- 206010012374 Depressed mood Diseases 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 102000002140 Fatty Acid-Binding Protein 7 Human genes 0.000 description 1
- 108010001387 Fatty Acid-Binding Protein 7 Proteins 0.000 description 1
- 208000024412 Friedreich ataxia Diseases 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 108700005000 Glial Fibrillary Acidic Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101000876829 Homo sapiens Protein C-ets-1 Proteins 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 208000018127 Idiopathic intracranial hypertension Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- 238000001276 Kolmogorov–Smirnov test Methods 0.000 description 1
- 201000005802 Landau-Kleffner Syndrome Diseases 0.000 description 1
- 208000009829 Lewy Body Disease Diseases 0.000 description 1
- 201000002832 Lewy body dementia Diseases 0.000 description 1
- 101150090066 MDE1 gene Proteins 0.000 description 1
- 208000002569 Machado-Joseph Disease Diseases 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 208000005314 Multi-Infarct Dementia Diseases 0.000 description 1
- 208000001089 Multiple system atrophy Diseases 0.000 description 1
- 102000047918 Myelin Basic Human genes 0.000 description 1
- 101710107068 Myelin basic protein Proteins 0.000 description 1
- 208000003926 Myelitis Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000027089 Parkinsonian disease Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102100035251 Protein C-ets-1 Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 101710192597 Protein map Proteins 0.000 description 1
- 108010023918 S100 Calcium Binding Protein beta Subunit Proteins 0.000 description 1
- 102000011425 S100 Calcium Binding Protein beta Subunit Human genes 0.000 description 1
- 101000974926 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Alcohol O-acetyltransferase 2 Proteins 0.000 description 1
- 208000029033 Spinal Cord disease Diseases 0.000 description 1
- 208000036834 Spinocerebellar ataxia type 3 Diseases 0.000 description 1
- 238000012896 Statistical algorithm Methods 0.000 description 1
- 108010021188 Superoxide Dismutase-1 Proteins 0.000 description 1
- 102100038836 Superoxide dismutase [Cu-Zn] Human genes 0.000 description 1
- 206010042928 Syringomyelia Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000009833 antibody interaction Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 230000007844 axonal damage Effects 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000010352 biotechnological method Methods 0.000 description 1
- 238000007413 biotinylation Methods 0.000 description 1
- 230000006287 biotinylation Effects 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 238000000533 capillary isoelectric focusing Methods 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000021235 carbamoylation Effects 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000022811 deglycosylation Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000000104 diagnostic biomarker Substances 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 238000011496 digital image analysis Methods 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-N diphosphoric acid Chemical compound OP(O)(=O)OP(O)(O)=O XPPKVPWEQAFLFU-UHFFFAOYSA-N 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- KAKKHKRHCKCAGH-UHFFFAOYSA-L disodium;(4-nitrophenyl) phosphate;hexahydrate Chemical compound O.O.O.O.O.O.[Na+].[Na+].[O-][N+](=O)C1=CC=C(OP([O-])([O-])=O)C=C1 KAKKHKRHCKCAGH-UHFFFAOYSA-L 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 201000006517 essential tremor Diseases 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 230000022244 formylation Effects 0.000 description 1
- 238000006170 formylation reaction Methods 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 208000003906 hydrocephalus Diseases 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000003961 neuronal insult Effects 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 238000000955 peptide mass fingerprinting Methods 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- RXNXLAHQOVLMIE-UHFFFAOYSA-N phenyl 10-methylacridin-10-ium-9-carboxylate Chemical compound C12=CC=CC=C2[N+](C)=C2C=CC=CC2=C1C(=O)OC1=CC=CC=C1 RXNXLAHQOVLMIE-UHFFFAOYSA-N 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 description 1
- 208000001381 pseudotumor cerebri Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000011506 response to oxidative stress Effects 0.000 description 1
- 238000011309 routine diagnosis Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 208000008864 scrapie Diseases 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 208000023516 stroke disease Diseases 0.000 description 1
- 238000004885 tandem mass spectrometry Methods 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 208000012720 thalamic disease Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000000954 titration curve Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000001419 two-dimensional polyacrylamide gel electrophoresis Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/02—Hepadnaviridae, e.g. hepatitis B virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
- C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
- C07K14/16—HIV-1 ; HIV-2
- C07K14/162—HIV-1 ; HIV-2 env, e.g. gp160, gp110/120, gp41, V3, peptid T, CD4-Binding site
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Communicable Diseases (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Neurology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Neurosurgery (AREA)
- Food Science & Technology (AREA)
- AIDS & HIV (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Enzymes And Modification Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Claims (11)
- DIAGNOSTISK FREMGANGSMÅDE FOR HJERNESKADERELATEREDE LIDELSER1. Fremgangsmåde til diagnosticering af en hjerneskaderelateret lidelse udvalgt fra hovedtraume, iskæmisk slagtilfælde, hæmoragisk slagtilfælde, subarachnoid hæmoragi, intrakranial hæmoragi, transitorisk iskæmisk attak og vaskulær demens eller muligheden derfor hos et subjekt der formodes at lide deraf, eller til prognose eller terapeutisk opfølgning af den hjemeskaderelaterede lidelse hos et subjekt, der omfatter påvisning af H-FABP og mindst ét yderligere polypeptid udvalgt fra RNA-bindingsregulerende subunit, ubiquitin-fusionsnedbrydningsprotein 1-homolog og nukleosiddiphosphatkinase A eller respektive varianter eller mutanter deraf med mindst 90 % homologi dermed og med i det væsentlige samme funktionelle og immunologiske egenskaber, i en prøve af kropsvæske taget fra subjektet, hvori H-FABP og det mindst ene yderligere polypeptid, eller varianten eller mutanten, er til stede i kropsvæsken hos subjekter, der er berørt af en hjemeskaderelateret lidelse, i en højere mængde sammenlignet med kropsvæsken hos subjekter, der ikke er berørt af en hjerneskaderelateret lidelse, hvorved en højere mængde af H-FABP og det mindst ene yderligere polypeptid, eller varianten eller mutanten, i kropsvæskeprøven er indikativ for den hjerneskaderelaterede lidelse.
- 2. Fremgangsmåde ifølge krav 1, hvori antistoffer mod H-FABP og det mindst ene yderligere polypeptid anvendes til påvisningen.
- 3. Fremgangsmåde ifølge krav 1 eller 2, hvori kropsvæsken er cerebrospinalvæske, plasma, serum eller blod.
- 4. Fremgangsmåde ifølge et hvilket som helst af kravene 1 til 3, omfattende påvisning af mindst ét yderligere polypeptid udvalgt fra PGP 9.5, GFAP, prostaglandin D-synthase, neuromodulin, neurofilament L, calcyphosin, glutathion S-tranferase P, cathepsin D, DJ-l-protein, peroxiredoxin 5 og peptidyl-prolyl cis-trans-isomerase A (cyclophilin A) eller en variant eller mutant deraf med mindst 90 % homologi dermed og med i det væsentlige samme funktionelle og immunologiske egenskaber.
- 5. Fremgangsmåde ifølge et hvilket som helst af kravene 1 til 4, hvori den hjerneskaderelaterede lidelse er slagtilfælde, og de yderligere polypeptider omfatter mindst to polypeptider udvalgt fra ubiquitin-fusionsnedbrydningsprotein 1-homolog, RNA-bindingsregulerende subunit og nukleosiddiphosphatkinase A.
- 6. Fremgangsmåde ifølge krav 5, hvori to eller flere antistoffer mod ubiquitin-fusionsnedbrydningsprotein 1-homolog, RNA-bindingsregulerende subunit, nukleosiddiphosphatkinase A og H-FABP anvendes i en enkelt brønd på en ELISA-mikrotiterplade, og fortrinsvis antistoffer mod alle fire markører anvendes i en enkelt brønd.
- 7. Fremgangsmåde ifølge krav 5 eller 6, hvori to eller flere polypeptider udvalgt fra ubiquitin-fusionsnedbrydningsprotein 1-homolog, RNA-bindingsregulerende subunit, nukleosiddiphosphatkinase A og H-FABP analyseres separat, og der anvendes en prædiktionsalgoritme til diagnosticering.
- 8. Anvendelse af H-FABP og mindst ét yderligere polypeptid udvalgt fra RNA-bindingsregulerende subunit, ubiquitin-fusionsnedbrydningsprotein 1-homolog og nukleosiddiphosphatkinase A, eller respektive varianter eller mutanter deraf med mindst 90 % homologi dermed og med i det væsentlige samme funktionelle og immunologiske egenskaber, og eventuelt mindst ét yderligere polypeptid udvalgt fra PGP 9.5, GFAP, prostaglandin D-synthase, neuromodulin, neurofilament L, calcyphosin, glutathion S-tranferase P, cathepsin D, DJ-1-protein, peroxiredoxin 5 og peptidyl-prolyl cis-trans-isomerase A (cyclophilin A), eller en variant eller mutant deraf med mindst 90 % homologi dermed og med i det væsentlige samme funktionelle og immunologiske egenskaber, til diagnostiske eller prognostiske applikationer i forhold til hjerneskaderelaterede lidelser udvalgt fra hovedtraume, iskæmisk slagtilfælde, hæmoragisk slagtilfælde, subarachnoid hæmoragi, intrakranial hæmoragi, transitorisk iskæmisk attak og vaskulær demens.
- 9. Anvendelse til diagnostiske og prognostiske applikationer i forhold til hjerneskaderelaterede lidelser udvalgt fra hovedtraume, iskæmisk slagtilfælde, hæmoragisk slagtilfælde, subarachnoid hæmoragi, intrakranial hæmoragi, transitorisk iskæmisk attak og vaskulær demens af antistoffer mod H-FABP og mindst ét yderligere polypeptid udvalgt fra RNA-bindingsregulerende subunit, ubiquitin-fusionsnedbrydningsprotein 1-homolog og nukleosiddiphosphatkinase A, eller respektive varianter eller mutanter deraf med mindst 90 % homologi dermed og med i det væsentlige samme funktionelle og immunologiske egenskaber, og eventuelt mindst ét yderligere polypeptid udvalgt fra PGP 9.5, GFAP, prostaglandin D-synthase, neuromodulin, neurofilament L, calcyphosin, glutathion S-tranferase P, cathepsin D, DJ-l-protein, peroxiredoxin 5 og peptidyl-prolyl cis-trans-isomerase A (cyclophilin A), eller en variant eller mutant deraf med mindst 90 % homologi dermed og med i det væsentlige samme funktionelle og immunologiske egenskaber.
- 10. Fremgangsmåde ifølge et hvilket som helst af kravene 1 til 7, hvori der anvendes en analyseanordning omfattende et fast substrat med et område, der indeholder antistoffer mod H-FABP og det mindst ene yderligere polypeptid eller varianterne eller mutanterne deraf.
- 11. Fremgangsmåde ifølge krav 10, hvori analyseanordningen har et unikt adresserbart område for hvert antistof og dermed tillader en analyseudlæsning for hvert enkelt polypeptid eller for enhver kombination af polypeptider.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0322063.9A GB0322063D0 (en) | 2003-09-20 | 2003-09-20 | Diagnostic method for brain damage-related disorders |
| GBGB0414089.3A GB0414089D0 (en) | 2003-09-20 | 2004-06-23 | Diagnostic method for brain damage-related disorders |
| GB0419068A GB0419068D0 (en) | 2003-09-20 | 2004-08-27 | Diagnostic method for brain damage-related disorders |
| PCT/GB2004/050012 WO2005029088A2 (en) | 2003-09-20 | 2004-09-20 | Diagnostic method for brain damage-related disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1664795T3 true DK1664795T3 (da) | 2018-02-12 |
Family
ID=29266361
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK04787496.1T DK1664795T3 (da) | 2003-09-20 | 2004-09-20 | Diagnostisk fremgangsmåde for hjerneskaderelaterede lidelser |
Country Status (4)
| Country | Link |
|---|---|
| CA (1) | CA2932077C (da) |
| DK (1) | DK1664795T3 (da) |
| ES (3) | ES2657442T3 (da) |
| GB (2) | GB0322063D0 (da) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO2324360T3 (da) * | 2008-08-11 | 2018-06-30 | ||
| CN109696549B (zh) * | 2017-10-20 | 2022-11-01 | 成都蓝瑙生物技术有限公司 | 用于脑中风的发光elisa体外诊断试剂盒 |
-
2003
- 2003-09-20 GB GBGB0322063.9A patent/GB0322063D0/en not_active Ceased
-
2004
- 2004-06-23 GB GBGB0414089.3A patent/GB0414089D0/en not_active Ceased
- 2004-09-20 ES ES10181193.3T patent/ES2657442T3/es active Active
- 2004-09-20 CA CA2932077A patent/CA2932077C/en active Active
- 2004-09-20 DK DK04787496.1T patent/DK1664795T3/da active
- 2004-09-20 ES ES04787496.1T patent/ES2657320T3/es active Active
- 2004-09-20 ES ES10181407.7T patent/ES2657422T3/es active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2932077C (en) | 2020-06-02 |
| CA2932077A1 (en) | 2005-03-31 |
| GB0414089D0 (en) | 2004-07-28 |
| ES2657422T3 (es) | 2018-03-05 |
| ES2657442T3 (es) | 2018-03-05 |
| ES2657320T3 (es) | 2018-03-02 |
| GB0322063D0 (en) | 2003-10-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2341350T3 (da) | Diagnostisk fremgangsmåde for hjerneskaderelaterede lidelser baseret på påvisning af dj-1 | |
| JP5281397B2 (ja) | 脳損傷関連障害の診断法 | |
| JP5775568B2 (ja) | 診断方法 | |
| US9738709B2 (en) | Methylated peptides derived from tau protein and their antibodies for diagnosis and therapy of alzheimer's disease | |
| WO2009152607A1 (en) | Methods and kits for diagnosing neurodegenerative disease | |
| DK2389587T3 (da) | Diagnostiske og prognostiske fremgangsmåder relateret Alzheimers sygdom | |
| JP4949026B2 (ja) | 卒中の診断方法 | |
| JP2005511063A (ja) | アルツハイマー病を検出する方法およびアルツハイマー病と他の痴呆疾患とを区別する方法、関連のペプチドおよびその使用 | |
| DK1664795T3 (da) | Diagnostisk fremgangsmåde for hjerneskaderelaterede lidelser | |
| AU2012257602B2 (en) | Methods and compositions relating to platelet sensitivity | |
| Herries et al. | Brain Biomarkers: Follow-Up of RNA Expression Discovery Approach: CSF Assays for Neurogranin, SNAP-25, and VILIP-1 | |
| Zimmermann-Ivol Catherine et al. | Fatty acid binding protein as a serum marker for the early diagnosis of stroke: a pilot study | |
| WO2020070363A1 (es) | Método para predecir o pronosticar la respuesta al tratamiento de la esclerosis múltiple con interferón beta. |